RxDoctor Payments Data

Amir Choudhry, MD

Cardiovascular Disease · Plano, TXNPI 1457388258

Payments from drug & device makers

$9,481in general payments, 2019–2025

Across 373 payments — averaging $25.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$1K
  • Johnson & Johnson$653
  • Medtronic$575
  • Merck$489
  • E.r. Squibb & Sons, L.L.C.$386
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$9,447100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,481 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$654,488
Medicare patients
1,008
Services billed
4,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban569$681,742
XareltoRivaroxaban62$82,241
EntrestoSacubitril/Valsartan47$64,054
Repatha SureclickEvolocumab25$25,045
BrilintaTicagrelor20$24,469
JardianceEmpagliflozin13$12,418
Praluent PenAlirocumab22$12,250
Metoprolol Succinate539$7,245
Repatha SyringeEvolocumab11$5,945
Atorvastatin Calcium434$3,384
Nifedipine ErNifedipine98$2,970
Losartan Potassium321$2,805
Ranolazine ErRanolazine21$2,643
Metoprolol Tartrate352$2,597
Amiodarone Hcl35$2,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$681,742569 claims
Johnson & JohnsonXarelto$653$82,24162 claims
NovartisEntresto$1,131$64,05447 claims
AstraZenecaBrilinta$213$24,46920 claims
Boehringer IngelheimJardiance$286$12,41813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →